Network pharmacology identified 156 intersecting targets between YHD and depression-related pathways, primarily involved in neuroactive ligand-receptor interactions, dopaminergic synapses, and inflammatory processes (e.g., TNF signaling and cytokine production). The gene discussed is TNF; the disease is depressive symptom measurement.